ArticleFrontiers in medicine2026
Effects of early vs. late administration of labetalol on maternal cerebral perfusion and fetal growth in severe pre-eclampsia.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe pre-eclampsia is a major contributor to maternal and perinatal morbidity and mortality worldwide. Antihypertensive therapy is essential, yet the impact of the timing of intravenous labetalol initiation on maternal cerebral hemodynamics and clinical outcomes remains uncertain, particularly in Chinese populations. Methods: In this retrospective cohort study, we evaluated women with severe pre-eclampsia treated at the Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Jiangsu Province, China, between March 2023 and July 2025. Women diagnosed with severe pre-eclampsia were categorized into two groups based on the timing of labetalol administration: early (≤60 min after diagnosis) and late (>60 min). Clinical characteristics, laboratory data, treatment details, and outcomes were retrieved from electronic records. Primary outcomes were changes in middle cerebral artery pulsatility index (MCA PI) and time to blood pressure control. Secondary outcomes included maternal complications (HELLP syndrome, acute kidney injury, pulmonary edema, intensive care unit admission, and maternal death) and neonatal outcomes (birthweight, small-for-gestational-age, NICU admission, neonatal complications, and perinatal death). Statistical analyses employed Welch's Results: Of 372 women screened, 320 were included (162 early-treatment and 158 late-treatment). Baseline demographic and laboratory profiles were comparable. Early labetalol initiation was associated with significantly greater increases in MCA PI at 60 min, 6 h, and 24 h ( Conclusion: Early initiation of intravenous labetalol was associated with improved maternal cerebral perfusion and more rapid blood pressure stabilization, without an increase in adverse maternal or neonatal outcomes. These findings highlight the importance of timely antihypertensive therapy in severe pre-eclampsia, although prospective studies are required to establish causality and long-term clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.